Jambo Runs for Melanoma Research

Approximately 17,000 people are diagnosed with melanoma skin cancer each year in the UK. Despite recent therapeutic advances, melanoma is still the most aggressive skin cancer, with a 15-20% 5-year survival rate. In the past 15 years, major progress has been made in the areas of immunotherapy and kinase inhibitors, now the the backbone of systemic therapy. Chemotherapy, on the other hand, is considered a second-line treatment option. Yet, we are still at the early stages of developing combined treatments for advanced stage melanomas, and ongoing research and clinical trial participation is essential to combat this disease.

After recently hearing about a friend's stage three diagnosis, and their need and want to explore alternative routes to chemo, I want to support ongoing cutting edge research to help treat this condition